GW Pharmaceuticals plc has received an U.S. Food and Drug Administration (FDA) has granted Fast Track designation for a proprietary intravenous form of cannabidiol (CBD) to treat Neonatal Hypoxic-Ischemic Encephalopathy (NHIE), and a orphan designation for the same product from The European…
This article has been re-posted from the April – May 2003 Cannabis Health Journal.
By Matt Elrod
In November 1998, a year before the Institute of Medicine [1] rekindled North American interest in cannabinoid research and the development of cannabis-based Pharmaceuticals, the UK House…